Bio-Rad Laboratories, Inc. BIO posted third-quarter 2024 adjusted earnings per share (EPS) of $2.01, which beat the Zacks Consensus Estimate by 57%. However, the bottom line decreased 13.7% from the prior-year...
Wall Street is sitting on its hands on Monday and Tuesday waiting for Alphabet, Microsoft, Apple, Amazon, and other mega-cap technology stocks to report their results in the final week of October.See the...
Walgreens Boots Alliance, Inc. WBA delivered adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2024, down 41.8% from the year-ago quarter’s figure (down 40.8% at constant...
Penumbra, Inc. PEN is likely to grow in the coming quarters, backed by the strength exhibited in the Thrombectomy business. The company’s robust portfolio expansion looks promising. However, the impact...
Chemed Corporation CHE is expected to grow in the upcoming quarters, backed by the prospects of the VITAS business. Strength within the company’s Roto-rooter brand looks impressive. Meanwhile, Chemed’s...
QIAGEN N.V. QGEN is well-poised to grow in the coming quarter, driven by its strategic alliances with researchers and pharma companies. The company’s expansive next-generation sequencing (NSG) portfolio...
Phibro Animal Health's PAHC diversified product portfolio and wide presence in key growth areas bolster our confidence in the stock. The stock carries a Zacks Rank #2 (Buy).Factors to Drive PAHC's GrowthPhibro’s...
Integra LifeSciences Holdings Corporation IART is well-poised to grow in the coming quarter, driven by healthy sales growth within its Tissue Technologies business despite product recall and manufacturing...